Chemotherapy with or without immune therapy for advanced lung cancer after initial treatment failure

This study is testing whether platinum-based chemotherapy combined with immune checkpoint inhibitors works better than chemotherapy alone for people whose advanced lung cancer has stopped responding to their first targeted treatment. The trial includes three groups based on the specific genetic mutations found in each person's cancer: EGFR, ALK, or ROS1 mutations. Researchers will track how well the treatment works and monitor for side effects.

Many people with these specific types of lung cancer eventually stop responding to their first targeted medication, and doctors need better options for what to do next. This trial is designed to see if adding the new immune-boosting medication to chemotherapy can help more patients when their cancer becomes resistant to initial therapy.